Balyasny Asset Management LLC Denali Therapeutics Inc. Transaction History

Balyasny Asset Management LLC

$58 Billion
Q3 2024

A detailed history of Balyasny Asset Management LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 45,108 shares of DNLI stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,108

Previous 120,612 62.6%

Holding current value

$1.11 Million

Previous $2.8 Million 53.11%

% of portfolio

0.0%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$20.96 - $31.05 $1.58 Million - $2.34 Million	-75,504 Reduced 62.6%	45,108 $1.31 Million
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $3.63 Million - $5.63 Million	-242,415 Reduced 66.78%	120,612 $2.8 Million
Q1 2024 May 13, 2024	BUY	$15.83 - $23.35 $1.62 Million - $2.39 Million	102,440 Added 39.31%	363,027 $7.45 Million
Q4 2023 Feb 14, 2024	BUY	$16.2 - $23.18 $4.22 Million - $6.04 Million	260,587 New	260,587 $5.59 Million
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $34,505 - $44,536	1,313 New	1,313 $36,000
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $373,346 - $608,553	-12,874 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $277,260 - $358,180	6,510 Added 102.29%	12,874 $574,000
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $4.63 Million - $7.48 Million	-95,570 Reduced 93.76%	6,364 $321,000
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $1.7 Million - $2.65 Million	33,832 Added 49.68%	101,934 $8 Million
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $969,906 - $1.47 Million	18,028 Added 36.0%	68,102 $3.89 Million
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $512,254 - $1.3 Million	-13,886 Reduced 21.71%	50,074 $4.19 Million
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $1.48 Million - $2.48 Million	63,960 New	63,960 $2.29 Million
Q2 2020 Aug 14, 2020	SELL	$16.01 - $28.82 $868,798 - $1.56 Million	-54,266 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $770,577 - $1.52 Million	54,266 New	54,266 $950,000
Q3 2019 Nov 14, 2019	SELL	$15.32 - $21.92 $1.84 Million - $2.64 Million	-120,402 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$18.5 - $28.14 $2.23 Million - $3.39 Million	120,402 New	120,402 $2.5 Million

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.31B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Denali Therapeutics Inc. Transaction History